You just read:

Cardiologists Continue to Lag Nephrologists When It Comes to the Adoption of Vifor/Relypsa's Veltassa for Hyperkalemia, but Prescribers in Both Specialties Report Mounting Market Access Pressure

News provided by

Spherix Global Insights

Nov 16, 2017, 11:26 ET